88IV - PR Newswire Asia's news - Biotechnology

< Previous page

| Title only | Print

Next page >

Samsung Biologics Announces KRW 3 Trillion Rights Offering to Fund Its Next-Phase Expansion INCHEON, South Korea , Aug. 28, 2026 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS) today announced a rights offering to raise an expected aggregate amount of KRW 3 trillion to fund investments in ... 2026-08-28T Biotechnology Chemical Health Care/Hospital Medical/Pharmaceuticals
Kazia Therapeutics Limited Announces Proposed Public Offering SYDNEY , Aug. 28, 2026 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA) ("Kazia" or the "Company"), an oncology-focused biotechnology company developing therapies ... 2026-08-28T Biotechnology Health Care/Hospital Medical/Pharmaceuticals
Kazia Therapeutics Reports 100% Clinical Benefit Rate in Initial Six Patients Treated for Advanced Triple-Negative Breast Cancer Durable Complete Metabolic Response Ongoing Since November 2025 ... 2026-08-28T Biotechnology Health Care/Hospital Medical/Pharmaceuticals
Global genomics and multi-omics leader Novogene to establish its first Australian laboratory at Cabrini Health, accelerating access to precision cancer care MELBOURNE, Australia , Aug. 28, 2026 /PRNewswire/ -- Global multi-omics leader Novogene is establishing its first Australian laboratory at Cabrini Health, bringing advanced genomic capabilities closer ... 2026-08-28T Biotechnology Health Care/Hospital Medical/Pharmaceuticals
Flexsys Narrows 6PPD Replacement to Two Final Molecules and Enters Cooperative Research and Development Agreement with U.S. Geological Survey for Independent Toxicity Testing These two steps bring a 6PPD replacement closer to market, as federal scientists will conduct extensive aquatic toxicity testing - a critical step toward final molecule selection and commercialization ... 2026-08-27T Biotechnology Chemical
CStone 2026 Interim Results: Accelerating Pipeline 2.0 Execution and Sustained Global Commercial Momentum CS2009 Achieved Key Clinical Validations for Efficacy and Safety ... 2026-08-27T Biotechnology Health Care/Hospital Medical/Pharmaceuticals
Harbour BioMed Appoints Mr. Youchen Chen and Dr. Ian Y. Liu as Executive Directors CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI , Aug. 27, 2026 /PRNewswire/ -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery ... 2026-08-27T Biotechnology Health Care/Hospital Medical/Pharmaceuticals
Harbour BioMed Reports 2026 Interim Results: Three Integrated Growth Engines Accelerate Execution of Its Platform-Based Strategy CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI , Aug. 27, 2026 /PRNewswire/ -- Harbour BioMed ("HBM" or the "Company"; HKEX: 02142), a global biopharmaceutical company committed ... 2026-08-27T Biotechnology Health Care/Hospital Medical Equipment Medical/Pharmaceuticals
ZEISS debuts DORC EVA NEXUS for cataract surgery at ESCRS Now spanning ZEISS Retina and Cataract Workflows, the EVA NEXUS ™ ophthalmic surgical system from ZEISS comes in a cataract-only configuration, bringing a tailored approach to different surgical ... 2026-08-27T Biotechnology Health Care/Hospital Medical Equipment Medical/Pharmaceuticals
Fosun International Reports 1H2026 Results: Total Revenue RMB86.96 Billion, Net Profit RMB1.72 Billion Highlights: ... 2026-08-27T Biotechnology Health Care/Hospital Medical/Pharmaceuticals

< Previous page

Next page >

88iv | Home | Login

Forum rule | About Us | Contact Info | Terms & Conditions | Privacy Statment | Disclaimer

Copyright (C) 2026

Suntek Computer Systems Limited.

All rights reserved